Piperazine Derivative D3 Receptor Ligand Selectivity

The patent applies local quality by designing a piperazine derivative with specific substituent patterns at defined positions (R1, R2, R3, R4, R5, R6, R7, R8) to achieve selective binding to D3 receptors. The structured substitution pattern ensures the compound interacts specifically with D3R binding sites while avoiding off-target effects on other dopamine receptors, thereby improving treatment efficacy and reducing side effects.

The patent employs parameter changes by systematically varying the chemical structure of the piperazine core through different substituent groups at multiple positions. By modifying parameters such as the type of aromatic rings, alkyl groups, and their positions on the piperazine scaffold, the invention optimizes D3R binding affinity and selectivity, enhancing therapeutic effectiveness while minimizing adverse effects.

The patent applies local quality by introducing specific functional groups at defined positions on the piperazine scaffold. The aromatic substituents at R1-R4 positions and the specific arrangement of heteroatoms create a localized binding interface that matches the D3 receptor binding pocket geometry, enhancing both selectivity and binding affinity through complementary molecular interactions.

The patent employs composite materials by combining multiple functional moieties into a single piperazine derivative molecule. The compound integrates aromatic rings, heteroatomic groups, and alkyl chains in a composite structure that synergistically enhances D3R binding properties, achieving high affinity and selectivity through the combined effect of different structural elements.